secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001477932-23-003238
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q1 sales jump 381% to $124k; cash $10M; expects $13M milestones
--------------------------------------------------------------------------

- Nu.Q Vet Cancer Test sales rose 381% YoY to $124,000 in Q1 2023.
- Cash and equivalents $10.0M at March 31, 2023 vs $10.9M at year-end 2022.
- Received ~$8M net from Feb public offering; expects $13M in Heska milestone payments and additional non-dilutive Belgian funding.
- Launched Nu.Q Vet Cancer Test through IDEXX and Heska; planning more country launches in 2023.
- Advancing Nu.Q NETs test for sepsis with multi-site U.S. studies and FDA Breakthrough Device application.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/0001477932-23-003238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-003238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer